Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

This phase II trial studies how well abemaciclib works in treating patients with ovarian or endometrial cancer that has an activation of the CDK4/6 pathway and that has come back (recurrent). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving abemaciclib may work better for the treatment of recurrent ovarian and endometrial cancer.

Trial Details

NCT ID

NCT04469764

Phase

PHASE2

Sponsor

Jonsson Comprehensive Cancer Center

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

Abemaciclib
Anastrozole
Letrozole

Locations (sample)

Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

Histologically-confirmed ovarian epithelial (including fallopian tube and primary peritoneal) cancer or endometrial cancer
Molecular tumor board confirms that patient's archival ovarian cancer tumor specimen has been assessed using standard of care genomic profiling and…
Molecular tumor board confirms that patient's archival endometrial cancer tumor specimen has been assessed using standard of care genomic profiling…
At least one prior chemotherapy regimen for the treatment of recurrent ovarian or endometrial cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →